Sore throat is a common and often distressing complication after laryngoscopy and endotracheal intubation (ETI), occurring in up to 70% of patients. This discomfort can lead to cough, swallowing difficulties, and decreased patient satisfaction. To mitigate this unpleasant side effect, various topical and systemic medications have been investigated as pre-intubation prophylaxis. This review compares the efficacy of adding magnesium sulfate, dexmedetomidine, and ondansetron to lidocaine for gargling before laryngoscopy and ETI in preventing sore throat.
Lidocaine gargle, a topical anesthetic, has been established as the standard pre-intubation prophylaxis for preventing sore throat. Its mechanism of action involves blocking sodium channels and inhibiting nerve impulses in the pharyngeal mucosa, reducing sensitivity to the trauma of laryngoscopy and ETI. Lidocaine generally shows modest efficacy, reducing the incidence and severity of sore throat by 10-20% compared to placebo.
Magnesium sulfate, a muscle relaxant with NMDA receptor antagonist properties, has emerged as a potential adjunct to lidocaine gargle. Studies suggest that magnesium may further reduce sore throat by:
Providing additional topical anesthesia in the pharynx.
Inhibiting central sensitization of pain pathways.
Acting as an anti-inflammatory agent.
Limited evidence suggests that adding magnesium sulfate to lidocaine gargle may offer a slight, but statistically significant, improvement in sore throat reduction compared to lidocaine alone. However, the clinical significance of this benefit remains debatable.
Dexmedetomidine, an alpha-2 receptor agonist, possesses sedative, analgesic, and anxiolytic properties. Its potential benefits in pre-intubation prophylaxis include:
Reducing anxiety and awareness of the procedure, potentially lessening the pain response.
Providing mild sedation, leading to less movement and airway manipulation during laryngoscopy and ETI.
Exerting some topical anesthetic effect on the pharyngeal mucosa.
Studies on adding dexmedetomidine to lidocaine gargle have shown mixed results. While some report a significant reduction in sore throat incidence and severity, others haven't found definitive improvement compared to lidocaine alone. Further research is needed to clarify the role of dexmedetomidine in this setting.
Ondansetron, a selective 5-HT3 receptor antagonist, primarily acts as an antiemetic to prevent nausea and vomiting. However, some studies have explored its potential in reducing sore throat by:
Inhibiting central sensitization of pain pathways in the brainstem.
Exerting an anti-inflammatory effect on the pharyngeal mucosa.
The evidence for ondansetron as an additive to lidocaine gargle for sore throat prevention is inconclusive. While some studies report modest benefits, others show no significant difference compared to lidocaine alone. Larger and well-designed trials are needed to definitively assess its efficacy.
While lidocaine gargle remains the standard pre-intubation prophylaxis for preventing sore throat, adding other agents like magnesium sulfate, dexmedetomidine, and ondansetron has shown limited additional benefit in some studies. The evidence for each agent is inconclusive, and further research is required to establish their definitive role and optimal dosing strategies. Individual patient factors and preferences should be considered when choosing the most appropriate pre-intubation prophylaxis regimen.
Investigating combinations of these agents with lidocaine to optimize efficacy while minimizing side effects.
Exploring novel topical agents and delivery methods for targeted pharyngeal anesthesia.
Studying the role of pre-emptive pain management strategies beyond gargling to further reduce post-intubation discomfort.
By continuing research and innovation, clinicians can strive to provide more effective and individualized preventive measures to minimize the burden of sore throat after laryngoscopy and ETI, enhancing patient comfort and satisfaction.
1.
A single-cell analysis reveals a distinctive immunosuppressive tumor microenvironment in kidney cancer brain metastases.
2.
The FDA approves Enhertu for HER2-positive cancers, regardless of tumor type.
3.
Cancer diagnosis does not spur improvements to survivors' diets or eating habits
4.
According to a study by Amrita Hospital in Kochi, cancer mortality is rising among Indian women while declining for men.
5.
A garden can save your life
1.
Reshaping the Battlefield Through Tumor Microenvironment Modulation for Cancer Therapy
2.
Understanding Epoetin and Its Role in Treating Chronic Kidney Disease
3.
Biologic Therapies for Cutaneous Immune-Related Adverse Events in the Era of Immune Checkpoint Inhibitors
4.
Cracking the Code of Subdural Hematomas: Modern Strategies for Optimal Care
5.
Imaging in Peritoneal Neoplasms: Diagnostic Advances and Multimodal Treatment Strategies
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
A Panel Discussion on Clinical Trial End Point for Tumor With PPS > 12 months
2.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part V
3.
An In-Depth Look At The Signs And Symptoms Of Lymphoma- Further Discussion
4.
Incidence of Lung Cancer- An Overview to Understand ALK Rearranged NSCLC
5.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part III
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation